Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy

Maria S Asdourian; Nishi Shah; Ted V Jacoby; Leah L Thompson; Tracey Otto; Yevgeniy R Semenov; Kerry L Reynolds; Steven T Chen

doi:10.1016/j.jaad.2022.05.015

Evaluating patterns of co-occurrence between cutaneous and noncutaneous immune-related adverse events after immune checkpoint inhibitor therapy

J Am Acad Dermatol. 2023 Jan;88(1):246-249. doi: 10.1016/j.jaad.2022.05.015. Epub 2022 May 13.

Authors

Maria S Asdourian¹, Nishi Shah², Ted V Jacoby³, Leah L Thompson¹, Tracey Otto⁴, Yevgeniy R Semenov¹, Kerry L Reynolds⁵, Steven T Chen⁶

Affiliations

¹ Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts.
² Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; Virginia Commonwealth University School of Medicine, Richmond, Virginia.
³ Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts; The University of Hawaii at Manoa John A. Burns School of Medicine, Honolulu, Hawaii.
⁴ Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey.
⁵ Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts; Department of Medicine, Division of Hematology and Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts.
⁶ Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts; Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts. Electronic address: [email protected].

No abstract available

Keywords: cutaneous immune-related adverse event; dermatologic toxicity; immune checkpoint inhibitor; immunotherapy; multisystem toxicity; noncutaneous immune-related adverse event.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Administration, Cutaneous
Humans
Immune Checkpoint Inhibitors* / adverse effects
Immunotherapy / adverse effects
Neoplasms* / drug therapy
Skin

Substances

Immune Checkpoint Inhibitors

Publication types

MeSH terms

Substances

Grants and funding